Shares of Evolent Health, Inc (NYSE: EVH - Get Free Report) crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.69 and traded as low as $2.62. Evolent Health shares last traded at $2.7850, with a volume of 2,872,468 shares traded. Analyst Ratings Changes A number
WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Shares of Evolent Health, Inc (NYSE: EVH - Get Free Report) have earned an average recommendation of "Moderate Buy" from the sixteen ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and fourteen have issued a buy recommendation on
WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, announced that the Compensation Committee of Evolent's Board of Directors approved the grant of a one-time time-based restricted stock unit award covering 587,500 shares of Evolent Class A common stock, par value $0.01 per share (the "Inducement Award"), to Mr. Mario Ramos ("Mr.
Investors need to pay close attention to EVH stock based on the movements in the options market lately.
Evolent Health, Inc. ( EVH ) UBS Global Healthcare Conference 2025 November 11, 2025 5:00 PM EST Company Participants John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Presentation Kevin Caliendo UBS Investment Bank, Research Division Good afternoon. This is Kevin Caliendo, health care service and distribution and IT analyst from UBS.
Evolent Health, Inc. ( EVH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Seth Blackley - Co-Founder, CEO & Director John Johnson - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Daniel Grosslight - Citigroup Inc., Research Division John Stansel - JPMorgan Chase & Co, Research Division Lucas Romanski - TD Cowen, Research Division Eduardo Ron - Truist Securities, Inc., Research Division Jeffrey Garro - Stephens Inc., Research Division Jessica Tassan - Piper Sandler & Co., Research Division David Larsen - BTIG, LLC, Research Division Matthew Shea - Needham & Company, LLC, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Presentation Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2025. As a reminder, this conference call is being recorded.
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Evolent Health (EVH) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.04 per share a year ago.
WASHINGTON , Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior authorization. The national partnership seeks to improve clinical decision-making by introducing quality-focused interventions, driving clinical insights through an innovative data and analytics platform, and rewarding providers for high-quality care.
